Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Total Liabilities : HK$62,185 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Total Liabilities?

Shanghai Fosun Pharmaceutical (Group) Co's Total Liabilities for the quarter that ended in Dec. 2023 was HK$62,185 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's quarterly Total Liabilities declined from Jun. 2023 (HK$62,010.55 Mil) to Sep. 2023 (HK$58,768.07 Mil) but then increased from Sep. 2023 (HK$58,768.07 Mil) to Dec. 2023 (HK$62,184.99 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual Total Liabilities increased from Dec. 2021 (HK$55,011.34 Mil) to Dec. 2022 (HK$59,247.30 Mil) and increased from Dec. 2022 (HK$59,247.30 Mil) to Dec. 2023 (HK$62,184.99 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Total Liabilities Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Total Liabilities Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

41,077.68

44,692.86

55,011.34

59,247.30

62,184.99

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															59,247.30	59,605.50	62,010.55	58,768.07	62,184.99

Shanghai Fosun Pharmaceutical (Group) Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Fosun Pharmaceutical (Group) Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	36923.333	+	(17013.197	+	8248.457
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	62,185

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	124110.658	-	61925.67
	=	62,185

Shanghai Fosun Pharmaceutical (Group) Co's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	36923.333	+	(17013.197	+	8248.457
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	62,185

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	124110.658	-	61925.67
	=	62,185

Shanghai Fosun Pharmaceutical (Group) Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (HKSE:02196) » Definitions » Total Liabilities

Traded in Other Exchanges

SFOSF:USA 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Headlines

No Headlines